Geneva, Switzerland, 21 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) has entered into a commercial license agreement for the use of Selexis’ technology and proprietary CHO-K1 cell line.
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific membrane antigen (PSMA) antibody. Financial terms were not disclosed.
“Progenics is an important oncology company, seeking to improve the lives of prostate cancer patients and their families. We at Selexis look forward to seeing the progress of the Progenics team in applying our proprietary cell line and technology platform to develop products going forward,” said Yemi Onakunle, PhD, vice president, licensing and business development, Selexis SA. “Our SUREtechnology Platform can facilitate rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum. It’s rewarding for us to list Progenics as one of our active commercial partners.”
